Welcome to our dedicated page for Precigen SEC filings (Ticker: PGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Precigen, Inc. filings document the company’s biopharmaceutical operations, commercial product disclosures, governance matters, and capital structure. Form 8-K reports cover financial results, PAPZIMEOS business updates, investor presentations, commercial supply arrangements, and financing agreements tied to the company’s transition into commercial-stage operations.
Precigen’s proxy materials describe board elections, auditor ratification, executive compensation votes, and equity incentive plan matters. Other filings disclose its Nasdaq-listed common stock, preferred-stock conversion activity, senior secured debt arrangements, material agreements, risk factors, and corporate governance controls relevant to a public precision-medicine company.
PRECIGEN, INC. Chief Financial Officer Harry Thomasian Jr. reported an open-market sale of 41,884 shares of common stock at $4.36 per share. According to the footnote, this sale was a sell-to-cover transaction to satisfy tax withholding obligations upon the vesting of restricted stock units on May 23, 2026. Following the transaction, he directly holds 554,535 shares of Precigen common stock.
PRECIGEN, INC. Chief Commercial Officer Phil Tennant reported a tax-related share sale. On May 28, 2026, he sold 30,272 shares of common stock at $4.36 per share in a sell-to-cover transaction tied to tax withholding on restricted stock units that vested on May 23, 2026. Following this transaction, he directly holds 139,369 common shares, and the filing shows no remaining derivative positions.
PRECIGEN, INC. Chief Operating Officer Rutul R. Shah reported a tax-related stock sale. On May 28, 2026, he sold 42,703 shares of common stock at $4.36 per share in a sell-to-cover transaction to satisfy tax withholding obligations from restricted stock units that vested on May 23, 2026. Following this transaction, he continues to hold 497,751 shares of Precigen common stock directly, indicating he retains a substantial equity stake in the company.
PRECIGEN, INC. reported an insider stock transaction by Chief Legal Officer Donald P. Lehr. On May 28, 2026, he sold 29,131 shares of common stock at $4.36 per share. According to the footnote, this was a sell-to-cover transaction to satisfy tax withholding obligations from restricted stock units that vested on May 23, 2026. After the sale, he continues to hold 755,461 shares of Precigen common stock directly.
PRECIGEN, INC. President and CEO Helen Sabzevari reported a disposition of company stock tied to tax obligations. She sold 119,250 shares of Common Stock at $4.36 per share in a sell-to-cover transaction to satisfy tax withholding upon the vesting of restricted stock units on May 23, 2026. Following this transaction, she directly holds 3,768,872 shares of Precigen common stock.
Precigen, Inc. Chief Financial Officer Harry Thomasian Jr. exercised restricted stock units into common stock as part of his compensation. On May 23, 2026, he acquired 87,500 shares of common stock through the conversion of restricted stock units, with no open-market purchase or sale reported.
Following the transaction, he directly holds 596,419 shares of common stock and 87,500 restricted stock units. The footnotes explain that these RSUs were granted on June 26, 2025, with 50% vesting on May 23, 2026 and the remaining units vesting in equal quarterly installments over the next three years.
PRECIGEN, INC. Chief Commercial Officer Phil Tennant acquired 62,500 shares of common stock on May 23, 2026 through the exercise of restricted stock units. Following the transaction, he directly holds 169,641 common shares. The filing also shows 62,500 RSUs remaining, which will vest in equal quarterly installments over three years.
PRECIGEN, INC. Chief Operating Officer Rutul R. Shah exercised 90,000 restricted stock units into common stock as part of his equity compensation. Following the transaction, he directly holds 540,454 shares of common stock and 90,000 RSUs. The footnotes state that these RSUs were part of a June 26, 2025 grant, with 50% vesting on May 23, 2026 and the remainder scheduled to vest in equal quarterly installments over three years. No open-market purchases or sales were reported; this activity reflects routine vesting and conversion of equity awards.
PRECIGEN, INC. President and CEO Helen Sabzevari exercised restricted stock units that converted into 250,000 shares of common stock on May 23, 2026. Following the transaction, she directly holds 3,888,122 shares of common stock, reflecting an increase in her equity position.
The Form 4 also shows 250,000 restricted stock units outstanding after the transaction. Each RSU represents a contingent right to receive one share of Precigen common stock. The vested portion represents 50% of RSUs granted on June 26, 2025, with the remaining RSUs scheduled to vest in equal quarterly installments over the next three years.
PRECIGEN, INC. Chief Legal Officer Donald P. Lehr exercised restricted stock units into common stock as part of his compensation. He acquired 62,500 shares of common stock on May 23, 2026, increasing his direct holdings to 784,592 shares.
The 62,500 RSUs exercised correspond to 50% of an RSU grant made on June 26, 2025 that vested on May 23, 2026. The remaining portion of that grant, represented by 62,500 RSUs, is scheduled to vest in equal quarterly installments over the next three years.